GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Researchers Identify Clinical Features Linked to Higher Risk of Profound Autism in Children

by GOAI
Share To

Researchers have identified key clinical features that may help distinguish children at risk of profound autism, a subset of autism spectrum disorder (ASD) characterized by significant challenges in communication, behavior, and daily functioning. This area of study focuses on understanding the complexities of ASD to better identify and support individuals who experience more severe impacts. The findings aim to provide insights into early identification and intervention strategies for those profoundly affected by the condition.

The research highlights specific markers that could indicate a higher likelihood of profound autism in children. These include limited verbal communication abilities, heightened sensory sensitivities, repetitive behaviors, and difficulties with social interactions. By analyzing these traits, researchers hope to refine diagnostic tools and improve access to tailored interventions. The study emphasizes the importance of distinguishing between varying levels of severity within the autism spectrum to address individual needs effectively.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top